Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers

Ghent University Hospital (UZ)

Status and phase

Completed

Phase 2

Conditions

Thyroid Cancer

Treatments

Diagnostic Test: PET/CT scan F18-PSMA-11

Study type

Interventional

Funder types

Other

Identifiers

BC-09501

Details and patient eligibility

About

Determine the diagnostic value of 18F-PSMA-11 in patients with iodine refractory thyroid cancer.

Enrollment

8 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient is 18 years or older.
Signed Informed Consent.
Subject is diagnosed with a histologically confirmed differentiated thyroid carcinoma, that is considered RAI refractory. There is evidence of persisting or recurrent disease, based on serum thyroglobulin levels and/or medical imaging.
Subject should have a routine clinical 18F-FDG PET/CT performed within two months prior to the study scan.
Female patients should be either post-menopausal, surgically sterile, or using highly effective contraceptives (methods that can achieve a failure rate of less than 1%: combined hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence).

Exclusion criteria

Patient has a known other active malignancy.
Subject is potentially pregnant (urinary test can be performed in case of doubt) or breastfeeding.
Patient is mentally or legally incapacitated.